



Exploring new options for **Skin Health in Individuals with Down Syndrome**

Mount Sinai is inviting individuals and families to take part in a **clinical research study** evaluating **abrocitinib**, an oral, once-daily investigational medication that works on immune pathways involved in eczema and alopecia, with the goal of improving quality of life.

G
C
N
Y

Who Can Join?

You or your loved one may be eligible if they:

- Are **12 years or older**
- Have **Down Syndrome**
- Have been diagnosed with **eczema (Atopic Dermatitis)** and/or **alopecia areata (hair loss)**

By joining, you can help researchers learn more about these conditions and contribute to future care for individuals with Down Syndrome.



Icahn
School of
Medicine at
Mount
Sinai



TO SIGN UP OR FOR
MORE INFORMATION,
PLEASE REACH OUT TO:

GISELLE SINGER
212.241.3288
GISELLE.SINGER@MSSM.EDU

Study Location: Mount Sinai Health System, Department of Dermatology, NYC
Principal Investigator: Dr. Emma Guttman, IRB #: 25-00773

Effective Date: 4/24/2026
End Date: 10/13/2026